StockTipsArenaBeta

BUY Piramal Pharma Limited — Shrikant Chouhan, Kotak Securities

BUYPiramal Pharma Limited
Piramal Pharma share price target & all analyst calls

byShrikant Chouhan, Kotak SecuritiesHorizon: NA (inferred Swing (≤2wk))6 Nov 2026via Zee Business (Live)

Entry₹238.8Inferred
Target₹250
Total upside +4.69%
Stop loss₹230-3.69% risk
CMP₹239.321d ago
Active+0.22%+4.46%upside left 13d left
Follow Shrikant Chouhan for new calls(32% target hit, 120 closed calls)Get alertsWatch PPLPHARMA for new buy/sell callsGet alertsSee 1 other Swing call on PPLPHARMASee 203 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:25 pm IST
10 supporting1 neutral1 opposing
Supports the BUY call (10)

MACD above its signal line — bullish momentum

Technicals · macd·7 Nov · today

2 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·4 Nov · 3d ago

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·2 Nov · 5d ago

Piramal Pharma shares surge 17% as Q2 revenue rises 28.1% YoY to ₹2,617 Cr and net profit turns positive to ₹5.6 Cr

NewsGoogle News·28 Oct · 1w ago

(opens in new tab)

Telecom could become one of Nifty’s biggest sectors after financials, says ICICI Securities

NewsCnbc-Tv18·28 Oct · 1w ago

(opens in new tab)
Neutral / worth noting (1)

Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·27 Oct · 1w ago

(opens in new tab)
Weighs against the BUY call (1)

RSI at 76 — overbought territory

Technicals · rsi·7 Nov · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Piramal Pharma

All analyst calls on Piramal Pharma

More from Shrikant Chouhan, Kotak Securities

Every call and its outcome